| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 3261- | Lyco, | Lycopene and Vascular Health |
| - | Review, | Stroke, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1710- | Lyco, | Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 8421- | Lyco, | Lycopene: Sojourn from kitchen to an effective therapy in Alzheimer's disease |
| - | Review, | AD, | NA |
| 8418- | Lyco, | docx, | A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients |
| - | Trial, | Pca, | NA |
| 8414- | Lyco, | Exploring the Therapeutic Potential of Lycopene: Mechanisms, Biological Activities, and Health Benefits |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8408- | Lyco, | Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial |
| - | Trial, | Nor, | NA |
| 4782- | Lyco, | New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene |
| - | Review, | Var, | NA |
| 4788- | Lyco, | Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review) |
| - | Review, | Var, | NA |
| 4801- | Lyco, | Lycopene in the Prevention of Cardiovascular Diseases |
| - | Review, | CardioV, | NA |
| 4796- | Lyco, | The Anti-proliferation Effects of Lycopene on Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 4792- | Lyco, | A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy |
| - | Review, | Var, | NA |
| 8727- | M-Blu, | High absolute bioavailability of methylene blue given as an aqueous oral formulation |
| - | Trial, | Nor, | NA |
| 8733- | M-Blu, | Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 2542- | M-Blu, | In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death |
| - | in-vitro, | Ovarian, | OV1369 | - | in-vitro, | Ovarian, | OV1946 | - | in-vitro, | Nor, | ARPE-19 |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 8495- | MAG, | Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats |
| - | in-vivo, | Nor, | NA |
| 8513- | MAG, | Magnolia extract is effective for the chemoprevention of oral cancer through its ability to inhibit mitochondrial respiration at complex I |
| - | vitro+vivo, | Oral, | SCC4 | - | in-vitro, | Tong, | SCC9 | - | in-vitro, | SCC, | CAL27 |
| 8512- | MAG, | Enhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation |
| - | in-vivo, | Nor, | NA |
| 8510- | MAG, | Pharmacokinetic and Metabolic Profiling of Key Active Components of Dietary Supplement Magnolia officinalis Extract for Prevention against Oral Carcinoma |
| - | in-vitro, | Oral, | CAL27 | - | in-vitro, | Tong, | SCC9 | - | in-vitro, | SCC, | SCC4 |
| 8504- | MAG, | Magnolol nanoparticles combat MRSA by disrupting TCA cycle and arginine metabolism to induce oxidative stress |
| - | in-vitro, | Var, | NA |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4525- | MAG, | HNK, | Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties |
| - | Study, | Nor, | NA |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 8538- | Matr, | Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | ex-vivo, | BC, | MDA-MB-231 |
| 8526- | Matr, | A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of Matrine |
| - | Review, | Nor, | NA |
| 8555- | Matr, | Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review |
| - | Review, | Var, | NA |
| 8551- | Matr, | Research Progress of Natural Matrine Compounds and Synthetic Matrine Derivatives |
| - | Review, | Nor, | NA |
| 8645- | MBZ, | HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo |
| - | vitro+vivo, | Colon, | CT26 |
| 8648- | MBZ, | Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature |
| - | Review, | Var, | NA |
| 8646- | MBZ, | Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion |
| - | in-vivo, | Var, | NA |
| 8812- | MCP, | Investigation of Antitumor Activity of Modified Citrus Pectin: Oral and Intravenous Administration Assessed via Molecular Imaging |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | in-vitro, | GC, | MKN-28 | - | in-vitro, | BC, | 4T1 |
| 8620- | MCT, | Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise Review |
| - | Review, | Nor, | NA |
| 6541- | MeSal, | Toxicology Answer: Oil of Wintergreen |
| - | Review, | Nor, | NA |
| 6537- | MeSal, | The ancient drug salicylate directly activates AMP-activated protein kinase |
| - | Review, | Nor, | NA |
| 8707- | MET, | Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8708- | MET, | Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients |
| - | Human, | Lung, | NA |
| 5795- | MET, | Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Diabetic, | NA |
| 2250- | MF, | MNPs, | Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field |
| - | Review, | Var, | NA |
| 3468- | MF, | An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing |
| - | Review, | Nor, | NA |
| 8462- | Mg, | Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study |
| - | Trial, | Nor, | NA |
| 782- | Mg, | Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial |
| - | Trial, | Var, | NA |
| 1782- | MLT, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 8673- | MLT, | Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications |
| - | Review, | GC, | NA |
| 8683- | MLT, | Intra-tumor ROS amplification by melatonin interferes in the apoptosis-autophagy-inflammation-EMT collusion in the breast tumor microenvironment |
| - | in-vivo, | BC, | NA |
| 656- | MNPs, | MF, | Effects of combined delivery of extremely low frequency electromagnetic field and magnetic Fe3O4 nanoparticles on hepatic cell lines |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 8901- | MOR, | Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex |
| - | in-vivo, | Nor, | NA |
| 8902- | MOR, | Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats |
| - | vitro+vivo, | Nor, | NA |
| 8903- | MOR, | QC, | Profound difference in pharmacokinetics between morin and its isomer quercetin in rats |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid